ArticleCancer discovery2014

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

Hikmat Al-Ahmadie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.